Bausch + Lomb Corp

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bausch + Lomb Corp reports stellar Q2 performance and raises guidance

Bausch + Lomb Corp's Q2 2024 earnings call showcased robust performance, with revenue growth, margin improvement, and raised guidance reflecting a strong outlook.
The company's emphasis on innovation, operational excellence, and long-term growth strategies highlights a commitment to sustained success and shareholder value.
While facing challenges in specific areas and competitive markets, Bausch + Lomb's focus on balancing growth, margins, and investments positions it well for future opportunities.

Bausch + Lomb Corp (BLCO) reports strong Q3 earnings and raises full-year guidance amidst strategic growth focus

Bausch + Lomb Corp (BLCO) delivered a strong Q3 performance with revenue growth, margin expansion, and raised full-year guidance, reflecting a solid financial outlook.
The company's focus on execution, product launches, and strategic investments is driving growth and profitability across segments, showcasing a resilient business strategy.
While challenges like market dynamics and operational complexities persist, opportunities in market expansion, innovation, and strategic partnerships offer avenues for sustained growth.
Overall, Bausch + Lomb Corp (BLCO) is well-positioned for continued success through its commitment to growth, innovation, and operational excellence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2024 Results Conference Call October 30, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brenton Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Xuyang Li - Jefferies Matt Miksic - Barclays Doug Miehm - RBC Capital Markets Lilia-Celine Lozada - JPMorgan Operator Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.

Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript

The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago.

Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates

It was quite a busy and eventful day for the company.

Why Bausch + Lomb Stock Soared by Over 7% on Monday

Bausch + Lomb Corporation (BLCO) shares popped Monday morning following reports Blackstone (BX) and TPG (TPG) are considering teaming up to buy the eyecare company.

Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid

Bausch + Lomb (BLCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?

The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal.

Why Bausch + Lomb Rallied Today

Bausch + Lomb (BLCO) shares popped Monday following a report that the eyecare company is considering a sale.

Bausch + Lomb Stock Jumps Amid Reports Of A Sale

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch & Lomb stock surged on reports the American-Canadian eye health products firm is exploring a sale as it seeks to resolve issues related to its separation from its debt-laden parent company Bausch Health Cos Inc (NYSE:BHC).    According to a Financial Times report citing people familiar with the matter, Bausch & Lomb is working with Goldman Sachs to gauge interest from potential buyers.

Bausch & Lomb reportedly exploring sale, shares rise

Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2024 Earnings Call July 31, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Robbie Marcus - JPMorgan Douglas Miehm - RBC Capital Markets Matt Miksic - Barclays Operator Good morning, and welcome to Bausch + Lomb's Second Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Bausch + Lomb Corporation (BLCO) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.18 per share a year ago.

Bausch + Lomb (BLCO) Matches Q2 Earnings Estimates

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from.

Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company's proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day co.

Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as little as two to four weeks.1,2* “We offer dry eye sufferers a wide array of options tha.

Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Nathalie Bernier 344,550,519 28.

Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry's Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024.

Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry's Meeting®

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. “enVista Envy is the next step in the dram.

Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens

Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants George Gadkowski - VP, IR & Business Insights Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Robbie Marcus - JPMorgan Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Matt Miksic - Barclays Doug Miehm - RBC Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.

Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. “Outperformance from each of our business units and solid results across geographies led to an impressive quarter and once again demonstrated our quality of growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our key franchises continue to deliver, and a focu.

Bausch + Lomb Announces First-Quarter 2024 Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the compa.

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published statistically significant results from a clinical study evaluating the efficacy and safety of a novel daily nutritional supplement formulated to address the symptoms of dry eyes.1 Bausch + Lomb expects to launch the supplement, which features a proprietary blend of ingredient.

Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue® Eye Care Recycling programs have collected 84,343,540 units, or 510,116 pounds, of used contact lenses, eye care and lens care materials in the U.S., which is greater than the weight of the Statue of Liberty.1 “Eye care professionals, patients and consumers have helped us collect hund.

News for Bausch + Lomb Corp Stock (BLCO)